Amgen Inc (AMGN)
319.22
-0.94
(-0.29%)
USD |
NASDAQ |
Nov 01, 16:00
317.56
-1.66
(-0.52%)
After-Hours: 20:00
Amgen Enterprise Value: 222.98B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 222.98B |
| October 31, 2024 | 223.48B |
| October 30, 2024 | 221.00B |
| October 29, 2024 | 221.25B |
| October 28, 2024 | 221.88B |
| October 25, 2024 | 221.77B |
| October 24, 2024 | 221.07B |
| October 23, 2024 | 220.65B |
| October 22, 2024 | 223.20B |
| October 21, 2024 | 221.63B |
| October 18, 2024 | 224.28B |
| October 17, 2024 | 224.10B |
| October 16, 2024 | 224.26B |
| October 15, 2024 | 226.12B |
| October 14, 2024 | 225.87B |
| October 11, 2024 | 227.88B |
| October 10, 2024 | 223.93B |
| October 09, 2024 | 224.68B |
| October 08, 2024 | 222.14B |
| October 07, 2024 | 222.02B |
| October 04, 2024 | 223.20B |
| October 03, 2024 | 222.03B |
| October 02, 2024 | 223.24B |
| October 01, 2024 | 223.56B |
| September 30, 2024 | 224.57B |
| Date | Value |
|---|---|
| September 27, 2024 | 226.72B |
| September 26, 2024 | 224.81B |
| September 25, 2024 | 221.45B |
| September 24, 2024 | 231.16B |
| September 23, 2024 | 233.68B |
| September 20, 2024 | 234.63B |
| September 19, 2024 | 233.86B |
| September 18, 2024 | 232.23B |
| September 17, 2024 | 232.17B |
| September 16, 2024 | 233.49B |
| September 13, 2024 | 231.98B |
| September 12, 2024 | 230.69B |
| September 11, 2024 | 230.65B |
| September 10, 2024 | 230.09B |
| September 09, 2024 | 228.47B |
| September 06, 2024 | 225.59B |
| September 05, 2024 | 227.63B |
| September 04, 2024 | 231.01B |
| September 03, 2024 | 230.94B |
| August 30, 2024 | 232.72B |
| August 29, 2024 | 231.21B |
| August 28, 2024 | 230.39B |
| August 27, 2024 | 229.01B |
| August 26, 2024 | 228.93B |
| August 23, 2024 | 230.02B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
128.48B
Minimum
Mar 12 2020
234.63B
Maximum
Sep 20 2024
168.61B
Average
161.54B
Median
Aug 03 2022
Enterprise Value Benchmarks
| Johnson & Johnson | 400.99B |
| Eli Lilly and Co | 805.11B |
| Merck & Co Inc | 284.75B |
| Regeneron Pharmaceuticals Inc | 84.89B |
| Viking Therapeutics Inc | 7.191B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.83B |
| Revenue (Quarterly) | 8.503B |
| Total Expenses (Quarterly) | 6.456B |
| EPS Diluted (Quarterly) | 5.22 |
| Gross Profit Margin (Quarterly) | 61.07% |
| Profit Margin (Quarterly) | 33.28% |
| Earnings Yield | 2.45% |
| Operating Earnings Yield | 3.61% |
| Normalized Earnings Yield | 2.447 |